A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
NCT01318421 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2015-12-14
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.
Conditions
Interventions
- DRUG
-
ELND002
Sponsors & Collaborators
-
Elan Pharmaceuticals
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-12-31
- Primary Completion
- 2012-12-31
More Related Trials
-
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
NCT03737851 ·Status: COMPLETED ·Phase: PHASE2
-
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
NCT02398461 ·Status: COMPLETED ·Phase: PHASE1
-
Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
NCT05116540 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
NCT03737812 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
NCT00213135 ·Status: COMPLETED ·Phase: PHASE3
-
Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis
NCT01745783 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Use of Technology to Improve MS Clinical Trials and Patient Care
NCT02454907 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse
NCT02633033 ·Status: COMPLETED
-
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis
NCT01056471 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00097760 ·Status: COMPLETED ·Phase: PHASE2
-
The MS-LINK™ Outcomes Study
NCT04735406 ·Status: COMPLETED
-
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
NCT02792231 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
NCT00203086 ·Status: COMPLETED
-
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
NCT01982942 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
NCT00030966 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
NCT00203073 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
NCT02792218 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of MD1003 in Spinal Progressive Multiple Sclerosis
NCT02220933 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses
NCT01900093 ·Status: UNKNOWN ·Phase: NA
-
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
NCT01405820 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
NCT00420212 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
NCT01081782 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
NCT00436826 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01464905 ·Status: UNKNOWN ·Phase: PHASE3
-
Extension Study of MT-1303
NCT01890655 ·Status: COMPLETED ·Phase: PHASE2